Navigation Links
French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent
Date:10/30/2009

NEWNAN, Ga., Oct. 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b )

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a )

The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA(TM) coronary stent for the treatment of up to three de novo native coronary artery lesions in a real word setting. "Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. "Physicians throughout France have already used the CATANIA(TM) stent, but this registry will increase participation over broad spectrum of new facilities to this stent without drugs on the surface and for which patient do not have to take long-term dual antiplatelet therapy."

The CATANIA(TM) stent is CE Marked and available throughout the European Union, in the Middle East, and Northern Africa. The stent, treated with CeloNova's anti-thrombotic and bacterial resistant Polyzene®-F surface is available in 60 sizes.

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit www.celonova.com

    CONTACT:  Teresa Wilson
              CeloNova BioSciences, Inc.
              +1 (678) 895-6486
              +1 (770) 502-0304
              twilson@celonova.com

SOURCE CeloNova BioSciences, Inc.


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ScienceDirect to Host French-Language Journals from Elsevier Masson
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
6. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
9. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Customers often prefer ... again and again. METTLER TOLEDO has released two new videos that show how ... integration of the ACT350 into Siemens and Allen Bradley PLCs is easy and ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... meeting and educational conference of the American Association of Bioanalysts (AAB) and the ... Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... , ... May 17, 2017 ... ... standards with psychonneuroendocrine stress expertise, and further enhances its scientific power by ... Douglas A. Granger, Ph.D., has agreed to join the scientific advisory board. ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):